Long-term prognostic value of preprocedural C-reactive protein after drug-eluting stent implantation.

[1]  J. Alpert,et al.  The universal definition of myocardial infarction , 2021, The ESC Textbook of Intensive and Acute Cardiovascular Care.

[2]  G. Lemesle,et al.  Preprocedural high-sensitivity C-reactive protein predicts death or myocardial infarction but not target vessel revascularization or stent thrombosis after percutaneous coronary intervention. , 2009, Cardiovascular revascularization medicine : including molecular interventions.

[3]  G. Lemesle,et al.  A Critical Appraisal of the Safety and Efficacy of Drug‐Eluting Stents , 2009, Clinical pharmacology and therapeutics.

[4]  Børge G Nordestgaard,et al.  Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial , 2009, The Lancet.

[5]  F. Burzotta,et al.  Association between C-reactive protein and angiographic restenosis after bare metal stents: an updated and comprehensive meta-analysis of 2747 patients. , 2008, Cardiovascular revascularization medicine : including molecular interventions.

[6]  Fred S Apple,et al.  Universal definition of myocardial infarction. , 2007, Journal of the American College of Cardiology.

[7]  A. Branzi,et al.  Predictive value of high sensitivity C-reactive protein in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention. , 2007, European heart journal.

[8]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[9]  M. Pfeffer,et al.  Prognostic Significance of the Centers for Disease Control/American Heart Association High-Sensitivity C-Reactive Protein Cut Points for Cardiovascular and Other Outcomes in Patients With Stable Coronary Artery Disease , 2007, Circulation.

[10]  Seung‐Jung Park,et al.  Prognostic impact of preprocedural C reactive protein levels on 6-month angiographic and 1-year clinical outcomes after drug-eluting stent implantation , 2007, Heart.

[11]  S. Ellis,et al.  Relation of C-reactive protein level and long-term risk of death or myocardial infarction following percutaneous coronary intervention with a sirolimus-eluting stent. , 2006, The American journal of cardiology.

[12]  Amy Shui,et al.  Clinical Relevance of C-Reactive Protein During Follow-Up of Patients With Acute Coronary Syndromes in the Aggrastat-to-Zocor Trial , 2006, Circulation.

[13]  P. Serruys,et al.  Persistence of neointimal growth 12 months after intervention and occurrence of delayed restenosis in patients with left main coronary artery disease treated with drug-eluting stents. , 2006, Journal of the American College of Cardiology.

[14]  N. Lamblin,et al.  High-sensitivity C-reactive protein: potential adjunct for risk stratification in patients with stable congestive heart failure. , 2005, European heart journal.

[15]  A. Kastrati,et al.  Comparison of C-reactive protein levels before and after coronary stenting and restenosis among patients treated with sirolimus-eluting versus bare metal stents. , 2005, The American journal of cardiology.

[16]  M. Pfeffer,et al.  C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.

[17]  R. Virmani,et al.  Drug-eluting stents: caution and concerns for long-term outcome , 2004, Coronary artery disease.

[18]  M. Hadamitzky,et al.  Association between C-reactive protein levels and subsequent cardiac events among patients with stable angina treated with coronary artery stenting. , 2003, The American journal of medicine.

[19]  J. Ambrose,et al.  The impact of plasma levels of C-reactive protein, lipoprotein (a) and homocysteine on the long-term prognosis after successful coronary stenting: The Global Evaluation of New Events and Restenosis After Stent Implantation Study. , 2002, Journal of the American College of Cardiology.

[20]  S. Marsch,et al.  Inflammation and Long-Term Mortality After Non-ST Elevation Acute Coronary Syndrome Treated With a Very Early Invasive Strategy in 1042 Consecutive Patients , 2002, Circulation.

[21]  Deepak L. Bhatt,et al.  Incremental Prognostic Value of Elevated Baseline C-Reactive Protein Among Established Markers of Risk in Percutaneous Coronary Intervention , 2001, Circulation.

[22]  S. Fichtlscherer,et al.  Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. , 2001, Journal of the American College of Cardiology.

[23]  P. Ridker,et al.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.

[24]  P. Libby,et al.  Novel inflammatory markers of coronary risk: theory versus practice. , 1999, Circulation.

[25]  M. Pfeffer,et al.  Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. , 1998, Circulation.

[26]  R. Ross,et al.  Atherosclerosis is an Inflammatory Disease , 1998 .

[27]  P. Ridker,et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[28]  S. Thompson,et al.  Production of C-reactive protein and risk of coronary events in stable and unstable angina , 1997, The Lancet.

[29]  M. Casl,et al.  Serum Amyloid a Protein in Patients with Acute Myocardial Infarction , 1995, Annals of clinical biochemistry.

[30]  A. Rebuzzi,et al.  The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. , 1994, The New England journal of medicine.